Johnson & Johnson (NYSE:JNJ) Stake Lessened by S.E.E.D. Planning Group LLC

Posted by Defense World Staff on Mar 31st, 2023

S.E.E.D. Planning Group LLC cut its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 4.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,586 shares of the company’s stock after selling 858 shares during the period. S.E.E.D. Planning Group LLC’s holdings in Johnson & Johnson were worth $3,460,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in JNJ. Veracity Capital LLC grew its stake in Johnson & Johnson by 1.2% in the 4th quarter. Veracity Capital LLC now owns 5,027 shares of the company’s stock valued at $888,000 after buying an additional 59 shares during the last quarter. Sandy Cove Advisors LLC grew its stake in Johnson & Johnson by 1.6% in the 3rd quarter. Sandy Cove Advisors LLC now owns 3,703 shares of the company’s stock valued at $605,000 after buying an additional 60 shares during the last quarter. Paces Ferry Wealth Advisors LLC grew its stake in Johnson & Johnson by 0.7% in the 3rd quarter. Paces Ferry Wealth Advisors LLC now owns 8,724 shares of the company’s stock valued at $1,425,000 after buying an additional 62 shares during the last quarter. Mason & Associates Inc grew its stake in Johnson & Johnson by 4.9% in the 3rd quarter. Mason & Associates Inc now owns 1,317 shares of the company’s stock valued at $215,000 after buying an additional 62 shares during the last quarter. Finally, Magnolia Capital Advisors LLC grew its stake in Johnson & Johnson by 0.7% in the 3rd quarter. Magnolia Capital Advisors LLC now owns 8,883 shares of the company’s stock valued at $1,451,000 after buying an additional 62 shares during the last quarter. 67.94% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

JNJ has been the topic of several research analyst reports. SVB Leerink decreased their price target on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a research report on Friday, January 20th. Guggenheim initiated coverage on shares of Johnson & Johnson in a research report on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 price target on the stock. Piper Sandler decreased their price target on shares of Johnson & Johnson from $55.00 to $52.00 in a research report on Monday, February 6th. StockNews.com assumed coverage on shares of Johnson & Johnson in a research report on Thursday, March 16th. They issued a “strong-buy” rating on the stock. Finally, UBS Group assumed coverage on shares of Johnson & Johnson in a report on Tuesday. They set a “neutral” rating and a $164.00 price objective for the company. Eight analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $173.67.

Johnson & Johnson Trading Up 0.1 %

Shares of JNJ stock opened at $153.43 on Friday. Johnson & Johnson has a 12-month low of $150.11 and a 12-month high of $186.69. The company has a market capitalization of $399.58 billion, a P/E ratio of 22.76, a P/E/G ratio of 2.64 and a beta of 0.54. The firm has a 50-day moving average price of $158.29 and a 200 day moving average price of $167.19. The company has a quick ratio of 0.77, a current ratio of 0.99 and a debt-to-equity ratio of 0.35.

Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, topping analysts’ consensus estimates of $2.22 by $0.13. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.76%. The company had revenue of $23.71 billion during the quarter, compared to the consensus estimate of $23.90 billion. During the same period in the previous year, the firm posted $2.13 earnings per share. The company’s revenue was down 4.4% on a year-over-year basis. Research analysts forecast that Johnson & Johnson will post 10.5 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st were paid a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.95%. The ex-dividend date of this dividend was Friday, February 17th. Johnson & Johnson’s dividend payout ratio is presently 67.06%.

Insiders Place Their Bets

In other news, insider James D. Swanson sold 1,062 shares of Johnson & Johnson stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the sale, the insider now owns 9,215 shares in the company, valued at approximately $1,425,191.90. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 0.35% of the company’s stock.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.